iiinova — where your digital self keeps evolving

Endpoints News @endpts.com · 22/09/2026

Thursday: Eleven private biotechs made the 2026 Endpoints 11. Join us for the gala dinner with the founders, investors and the editors who chose them. Can't make the gala? The Sept. 28 virtual experience is free. Register now. events.endpoints.news/eleven26/123...

000

Endpoints News @endpts.com · 21/09/2026

Rep. John Moolenaar is leading the push for legislation that would restrict US investment in China’s biotech industry. He sat down with Endpoints’ senior reporter Max Bayer to talk about his approach to the issue during Endpoints’ China Biotech Debate in Washington, DC.

000

Endpoints News @endpts.com · 18/09/2026

What are the consequences if biotech companies start keeping their science secret? For one — “we’re going to make shitty investment decisions,” said Patrick Malone, partner at KdT Ventures, during our China Biotech Debate in DC. Catch up on the full conversation: www.youtube.com/watch?v=HDt9...

012

Endpoints News @endpts.com · 15/09/2026

Since 2018, Endpoints editors have named 77 private biotechs to the Endpoints 11. Sixteen are public now, 16 were acquired, six have an approved drug, five are gone. The 2026 class is revealed Sept. 24 in Boston. Reserve your gala seat or a free virtual pass: events.endpoints.news/eleven26/123...

The Endpoints 11: Where are they now
Endpoints has honored 77 promising biotech startups since its first awards.

011

Endpoints News @endpts.com · 13/08/2026

Does big pharma’s calculus around drug development change if the bulk of the biopharma industry ends up shifting to China? Pfizer’s Andrew Baum said probably not — but that investment in the US would still matter.

111

Endpoints News @endpts.com · 12/08/2026

If laws prevented RA Capital Management's Peter Kolchinsky from investing in Chinese companies, he’d stop meeting with Chinese companies — but those dollars wouldn’t necessarily just go back to the US, he said during Endpoints’ China event.

100

Endpoints News @endpts.com · 11/08/2026

The US has spent the last decade spending more and more money to develop less innovative medicines, says Jake Becraft, Strand Therapeutics CEO. Any response to China’s increasing biotech edge has to include reforms that address that root issue, he said during Endpoints’ China event.

121

Endpoints News @endpts.com · 05/08/2026

Jeremy Levin was “deeply puzzled” by the reports that AstraZeneca and Bristol Myers were considering a megadeal. Levin, chairman of Ovid Therapeutics and former executive at BMS, told Post-Hoc Live Tuesday that there's no real rationale for big companies to get bigger:

110

Endpoints News @endpts.com · 23/06/2026

What's it going to take to keep the biotech industry in the US strong? Policy trying to slow the rise of China isn't enough, said John Stanford, executive director of Incubate, on Post-Hoc Live this week — leaders have to actively strengthen the domestic ecosystem.

100

Endpoints News @endpts.com · 17/03/2026

Tomorrow at noon ET: The patent cliff is closing in — and the dealmaking math is shifting fast. Join @drewsnews.bsky.social, along with Financial Times’ Patrick Temple-West and Oliver Barnes, for a quick breakdown of what’s next. Register to watch for free: capitalcompetitionpatent.live.ft.com

000

Endpoints News @endpts.com · 14/01/2026

How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism. Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...

011

Endpoints News @endpts.com · 13/01/2026

Endpoints reporters wrapped up our Main Stage programming with a roundtable on the regulatory environment, China, and everything else they're watching for the year ahead. Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.

000

Endpoints News @endpts.com · 13/01/2026

Live from Endpoints at #JPM26: Nobel Laureate Fred Ramsdell worries that the US is ceding its leadership position on cell therapy to China. "I think we risk losing that if we don't continue to invest in this field." Join us virtually for the rest of the day’s programming: events.endpoints.news/jpm26

020

Endpoints News @endpts.com · 12/01/2026

The pharmaceutical industry is slow by nature, Novo Nordisk CEO Mike Doustdar said at the Endpoints at #JPM26 event this morning. But he thinks it can get faster.

110

Endpoints News @endpts.com · 04/11/2025

What does Big Pharma really think of the UK? @financialtimes.com global pharmaceutical editor Hannah Kuchler joins us to break down how drugmakers are operating across the pond. Live today at 11 AM ET. endpoints.news/post-hoc-liv...

000

Endpoints News @endpts.com · 28/10/2025

Health tech is attracting capital and defying the downturn: from wearable tech to RWE, momentum is building. Join our online sessions in the morning, and in the evening we’re live in person with a reception at NYC’s Book Club Bar. Get your spot: events.endpoints.news/healthtech20...

000

Endpoints News @endpts.com · 21/10/2025

Tomorrow: ESMO 2025 delivered pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register to watch: events.endpoints.news/esmo2025/reg...

000

Endpoints News @endpts.com · 16/10/2025

Health tech is taking center stage — from wearables to RWE shaping pharma’s future. Join us Nov. 6 for online sessions in the morning, then meet us in person for a reception at NYC’s Book Club Bar. Seats are limited — reserve your spot now: events.endpoints.news/healthtech20...

000

Endpoints News @endpts.com · 22/09/2025

Meet our winners of the Endpoints 11! Last week, we announced the honorees at our annual gala in Boston—handpicked by our newsroom. They represent the best and brightest in biotech, and we'll be following every step. Congratulations! endpoints.news/the-2025-win...

000

Endpoints News @endpts.com · 19/09/2025

Umoja Biopharma: endpoints.news/endpoints-11...

000

Endpoints News @endpts.com · 19/09/2025

Third Arc Bio: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Stylus Medicines: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Sironax: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Orbis Medicines: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Lila Sciences: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Judo Bio: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Dispatch Biotherapeutics: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Chai Discovery: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Candid Therapeutics: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 19/09/2025

Averna Therapeutics: endpoints.news/endpoints-11...

100

Endpoints News @endpts.com · 21/08/2025

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Get your ticket today to save with Early Bird: events.endpoints.news/eleven25/883...

000

Endpoints News @endpts.com · 13/08/2025

RFK Jr.'s mRNA funding cuts aren't justified, Admiral Brett Giroir, former US bio-preparedness official, said on Post-Hoc Live. "I thought the whole premise was wrong. The facts that were stated were not facts at all."

112

Endpoints News @endpts.com · 08/08/2025

The mood in biopharma this quarter hasn’t been great — and the chaotic policy environment isn’t helping, said BMO's Evan Seigerman on Post-Hoc Live Thursday. He joined the show to take stock of Q2 earnings and look ahead to what comes next.

100

Endpoints News @endpts.com · 21/07/2025

In case you missed it – Varda Space Industries' CSO Adrian Radocea came to Post-Hoc Live last week to discuss what happens when drugs are formulated in orbit, and come back down to earth. Watch it here: www.youtube.com/live/sZ_Ow1d...

000

Endpoints News @endpts.com · 16/05/2025

What’s keeping biotech execs up at night in the Trump 2.0 era? Join @endpts.com founding editor John Carroll on May 20 for a deep dive into the latest Endpoints 100 survey — and what it signals for the future of the industry. events.endpts.com/e100-april20...

000

Endpoints News @endpts.com · 08/05/2025

The US Pharma and Biotech Summit 2025 takes place next week in New York at Convene, One Liberty Plaza. Join Endpoints News editors, biopharma CEOs, investors & policymakers for in-depth discussions on innovation, AI & the future of healthcare. Join us: uspharma.live.ft.com?utm_source=l...

000

Endpoints News @endpts.com · 01/04/2025

Are you at the FDA and affected by today's cuts? Reach out to our reporter @zacharybrennan.bsky.social (contact in his bio)

011

Endpoints News @endpts.com · 20/02/2025

AI and new modalities are reshaping drug discovery — but who’s making real progress? Join leading experts for a deep dive into the breakthroughs, challenges & future of early-stage R&D. Register today: events.endpts.com/drugday25/re...

011

Endpoints News @endpts.com · 18/02/2025

Who are the top 100 biotech VCs shaping the industry's future? Join Endpoints’ founding editor John Carroll and DealForma’s Chris Dokomajilar on Feb. 25 as they dive into biotech’s top investors, key trends, and what’s next for funding, IPOs, and M&A. events.endpts.com/top-100-vcs-...

000

Endpoints News @endpts.com · 30/01/2025

Catch up on all of the sessions from Endpoints at #JPM25, including conversations with former FDA Commissioner Scott Gottlieb and Nobel laureate Jennifer Doudna — visit our on-demand hub to watch now. events.endpts.com/jpm25/on-dem...

021

Endpoints News @endpts.com · 14/01/2025

Endpoints reporters wrapped up our event with a roundtable on the dealmaking environment, Trump 2.0, China, and everything else they're watching for the year ahead. Follow more of what they’re hearing on the ground in SF on the live blog: endpts.com/jpm25-day-2-...

000

Endpoints News @endpts.com · 14/01/2025

Umoja Biopharma lands 2025’s 10th megaround with a $100M Series C to advance in vivo CAR-T cell therapies for faster, less toxic cancer & autoimmune treatments. endpts.com/umojas-100m-...

031

Endpoints News @endpts.com · 14/01/2025

JPM woke up Monday to a spate of early deals, including J&J’s acquisition of Intra-Cellular Therapies. But on the Endpoints at #JPM25 stage, insiders were mixed on what that signaled for the year ahead. Today, we’ll be watching for more clarity on the 2025 outlook: endpts.com/jpm25-day-2-...

010

Endpoints News @endpts.com · 13/01/2025

Day 1 of the Endpoints at #JPM25 event is about to kick off with an interview with Xaira CEO Marc Tessier-Lavigne. Register for free to watch the live stream: events.endpts.com/jpm25/697639...

161

Endpoints News @endpts.com · 08/01/2025

Next week at #JPM25: "Leading a Billion-Dollar AI Biotech" with Marc Tessier-Lavigne. Hear how Xaira Therapeutics, 2024’s $1B launch, is set to reshape drug R&D with AI. Don’t miss this in-depth conversation. Join us live or online: events.endpts.com/jpm25/697639...

031

Endpoints News @endpts.com · 02/01/2025

Join Janet Woodcock at Endpoints at #JPM25 as she reflects on her FDA career and shares insights on the agency’s future direction. Our agenda is packed with 30+ industry pioneers & thought leaders — you won’t want to miss this year's lineup. Reserve your spot today: events.endpts.com/jpm25/697639...

001

Endpoints News @endpts.com · 02/01/2025

Biotech investors focused on clinical-stage companies in 2024, hoping their capital would fund key data readouts. But based on Endpoints' tally, preclinical startups were still somewhat in favor. endpts.com/the-top-biot...

042

Endpoints News @endpts.com · 30/12/2024

Escape the #JPM25 chaos at the Endpoints Hub—your coworking haven with private meeting spaces, coffee, meals, and networking opportunities. All pass purchases include Hub access, and you can bring colleagues with a Guest Pass for flexible access. Reserve your spot: events.endpts.com/jpm25/697639...

010

Endpoints News @endpts.com · 26/12/2024

Join us in person or virtually at Endpoints at #JPM25 for insights on the M&A landscape with Eric Tokat, Co-President of Centerview Partners. One of many sessions exploring the forces shaping 2025 and beyond. Reserve your spot now: events.endpts.com/jpm25/697639...

000